MODELS FOR COLLABORATIONS AND COMPUTATIONAL BIOLOGY - Collaborative Computational Technologies for Biomedical Research - page 45

Regulatory
Scientists

Neutral
Party

Industry
Scientists

Academic
Scientists

Figure 3.1 Schemata of relationships of stakeholder groups for PSTC.

patient advocacy, and other nonprofi t organizations. This multistakeholder
consortium was launched in October 2006 with the mission of joint discovery,
development, and qualifi cation of biomarkers. More specifi cally, the BC's
products and outcomes include (1) identifi cation and execution of cross-
sectoral biomarker projects, (2) publications, and (3) cross-sector familiariza-
tion, increased trust, new approaches to collaboration, and improved cultural
competency among the more than 60 participating organizations, agencies, and
companies.
One hallmark of the BC is that there is an absolute requirement that the
founding members participate in all activities and at every level (e.g., executive
and steering committees, project teams and subteams, and work groups) of
the BC.
To date, the consortium has implemented 10 projects in areas such as
Alzheimer's disease, cardiovascular disease, and cancer imaging; a number of
other promising projects are also moving forward for implementation. The BC
completed its fi rst project, titled “Evaluate the Utility of Adiponectin as a
Biomarker Predictive of Glycemic Effi cacy by Pooling Existing Clinical Trial
Data from Previously Conducted Studies” (adiponectin study) in 2009.
The results from the adiponectin study were published in June 2009 [4].
Conducted entirely via in-kind contributions from F. Hoffman LaRoche,
GlaxoSmithKline, Merck & Co, and Quintiles Translational Corporation, the
project involved aggregating data from clinical trials of peroxisome proliferator-
activated receptor (PPAR) agonists at GlaxoSmithKline, Eli Lilly, Merck, and
Roche. These pooled data were then subjected to analysis by statisticians at